The effects of excipients on transporter mediated absorption

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 17-31

  Goole, Jonathan ^a,b   Lindley, David J ^a   Roth, Wyatt ^a   Carl, Stephen M ^a   Amighi, Karim ^b   Kauffmann, Jean Michel ^b   Knipp, Gregory T ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Absorption; Excipients; Pharmaceutics; Transporters

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CARBOXYMETHYLCELLULOSE; CARRIER PROTEIN; COLCHICINE; CREMOPHOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EXCIPIENT; FILLER; FLUOROURACIL; GLYCERYL TRINITRATE; IMMUNOGLOBULIN; ISOSORBIDE DINITRATE; LOPERAMIDE; MACROGOL; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; POLOXAMER; POLYMER; SURFACTANT; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TREATMENT FAILURE; HUMAN; INTESTINE ABSORPTION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EXCIPIENTS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; KINETICS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953359223     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.019     Document Type: Review

References (117)

1. Akiyama S.I., Cornwell M.M., Kuwano M., Pastan I., Gottesman M.M. Most drugs that reverse multidrug resistance also inhibit photoaffinity labelling of P-glycoprotein by vinblastine analog. Mol. Pharmacol. 1988, 33:144-147.
2. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
3. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
4. Anderberg E.K., Artursson P. Epithelial transport of drugs in cell culture. VII. Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelia. J. Pharm. Sci. 1992, 81:879-887.
5. Anderle P., Huang Y., Sadee W. Intestinal membrane transport of drugs and nutriments: genomics of membrane transporters using expression microarrays. Eur. J. Pharm. Sci. 2004, 21:17-24.
6. Anderson J.M., Van Itallie C.M. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 1995, 269:G467-G475.
7. Arima H., Yunomae K., Hirayama F., Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral biavailability of tacrolimus. J. Pharmacol. Exp. Ther. 2001, 297:547-555.
8. Arima H., Yunomae K., Morikawa T., Hirayama F., Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastin-resistant Caco-2 cell monolayers. Pharm. Res. 2004, 21:625-634.
9. Badawy S.I.F., Gray D.B., Zhao F., Sun D., Schuster A.E., Hussain M.A. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm. Res. 2006, 23:989-996.
10. Baggetto L.G., Testa-Parussini R. Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: its contribution to membrane cholesterol enrichment modifying passive proton permeability. Arch. Biochem. Biophys. 1990, 283:241-248.
11. Baird A.W., Taylor C.T., Brayden D.J. Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue. Adv. Drug Del. Rev. 1997, 23:111-120.
12. Balimane P.V., Chong S. Biopharmaceutics applications in drug development. Evaluation of Permeability and P-glycoprotein Interactions: Industry Outlook 2008, 101-138. Springer, USA. Krishna-Yu (Ed.).
13. Barakat S., Gayet L., Dayan G., Labialle S., Lazar A., Oleinikov V., Coleman A.W., Baggetto L.G. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis. Biochem. J. 2005, 388:563-571.
14. Barbour N.P., Lipper R.A. Biopharmaceutics applications in drug development. Introduction to Biopharmaceutics and its Role in Drug Development 2008, 1-25. Springer, USA. Krishna-Yu (Ed.).
15. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 1999, 16:1366-1372.
16. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 2004, 21:2226-2233.
17. Bhardwaj R.K., Herrera-Ruiz D.R., Xu Y., Carl S.M., Cook T.J., Vorsa N., Knipp G.T. Biopharmaceutics applications in drug development. Intestinal Transporters in Drug Absorption 2008, 175-261. Springer, USA. Krishna-Yu (Ed.).
18. Bravo-Osuna I., Millotti G., Vauthier C., Ponchel G. In vitro evaluation of calcium binding capacity of chitosan and thiolated chitosan poly(isobutylcyanoacrylate) core-shell nanoparticles. Pharm. Nanotechnol. 2007, 338:284-290.
19. Bromberg L., Alakhov V. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Control. Release 2003, 88:11-22.
20. Budworth J., Grant T.W., Gescher A. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br. J. Cancer 1997, 75:1330-1335.
21. Cerf E., Gasper R., Rychnovsky S., Chang X.-B., Buyse F., Ruysschaert J.-M. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem. Biophys. Res. Commun. 2007, 355:1025-1030.
22. Cha S.H., Sekine T., Kusuhara H., Yu E., Kim J.Y., Kim D.K., Sugiyama Y., Kanai Y., Endou H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 2000, 275:4507-4512.
23. Chen C.J., Chin J.E., Ueda K., Pastan O., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistance human cells. Cell 1986, 47:381-389.
24. Chiang C.D., Song E.-J., Yang V.C., Chao C.C-K. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem. J. 1994, 301:759-764.
25. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Steward A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
26. Collnot E.-V., Baldes C., Wempe M.F., Kappl R., Hüttermann J., Hyatt J.A., Edgar K.J., Schaefer U.F., Lehr C.-M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence of ATPase activity and membrane fluidity. Mol. Pharm. 2007, 4:465-474.
27. Degim Z., Ünal N., Essiz D., Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monlayer. Life Sci. 2004, 75:2819-2827.
28. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 1999, 16:1550-1556.
29. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15665-15670. (Erratum in: Proc. Natl. Acad. Sci. U.S.A. 96, 2569).
30. Eisenblatter T., Galla H.J. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Commun. 2002, 293:1273-1278.
31. El-Masry E.M., Abou-Donia M.B. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid. Life Sci. 2003, 73:981-991.
32. Fagerholm U., Johansson M., Lennernäs H. Comparison between permeability coefficients in rat human jejunum. Pharmacol. Res. 1996, 13:1336-1341.
33. Farges R.C., Spillere de Silva M.B., Fröde T.S. Implication of glucocortocoid in anti-inflammatory effects of Ro5-4864 in mouse pleurisy induced by carrageenan. Life Sci. 2006, 78:1814-1822.
34. Ferte J. Analysis of tangled relationship between P-glycprotein mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 2000, 267:277-294.
35. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62:385-427.
36. Gutmann H., Hruz P., Zimmermann C., Beglinger C., Drewe J. Distribution of breast cancer resitance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 2005, 70:695-699.
37. Halestrap A.P., Price N.T. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J. 1999, 343:281-299.
38. Halici Z., Dengiz G.O., Odabasoglu F., Suleyman H., Cadirci E., Halici M. Amiodarone has anti-inflammatory and anti-oxydative properties: an experimental study in rats with carrageenan-induced paw edema. Eur. J. Pharmacol. 2007, 566:215-221.
39. Hansen J.E., Weisbart R.H., Nishimura R.N. Antibody mediated transduction of therapeutic proteins into living cells. Sci. World J. 2005, 5:782-788.
40. Hartmann G., Kim H., Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol. 2001, 1:189-199.
41. Hediger M.A., Romero M.F., Peng J.B., Rolfs A., Takanaga H., Bruford E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins Introduction. Pflugers Arch. 2004, 447:465-468.
42. Hewson L., Hollowood T., Chandra S., Hort J. Taste-aroma interactions in a citrus flavoured model beverage system: similarities and differences between acid and sugar type. Food Qual. Prefer. 2008, 19:323-334.
43. Higgins C.F. Molecular basis of multidrug resistance mediated by P-glycoprotein. Curr. Opin. Biotechnol. 1991, 2:278-281.
44. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem. Sci. 1992, 17:18-21.
45. Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Perspect. Clin. Pharmacol. 2005, 260-277.
46. Hugger E.D., Audus K.L., Borchardt R.T. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 2002, 91:1980-1990.
47. Hugger E.D., Novak B.L., Burton P.S., Audus K.L., Borchardt R.T. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 2002, 91:1991-2002.
48. Iga K., Ogawa Y. Sustained-release buccal dosage forms for nitroglycerin and isosorbide dinitrate: increased bioavailability and extended time of absorption when administered to dogs. J. Control. Release 1997, 49:105-113.
49. Ingels F., Beck B., Oth M., Augustijns P. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int. J. Pharm. 2004, 274:221-232.
50. Ingels F., Deferme S., Destexhe E., Oth M., Van den Mooter G., Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 2002, 232:183-192.
51. Johansson F., Hjertberg E., Eirefelt S., Tronde A., Bengtsson U.H. Mechanism for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 2002, 17:63-71.
52. Kalitsky-Szirtes J., Shayeganpour A., Brokcs D.R., Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos. 2004, 32:20-27.
53. Katneni K., Charman S.A., Porter C.J. Impact of Cremophor-EL and Polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J. Pharm. Sci. 2007, 96:280-293.
54. Kearsley N.L., Campbell A., Sanderson A.A., Weir R.D., Kamdar M.K., Coles S.J. Comparison of clarithromycin suspension and amoxicillin syrup for the treatment of children with pharyngitis and/or tonsillitis. Br. J. Clin. Pract. 1997, 51:133-137.
55. Kilsdonk E.P.C., Yancey P.G., Stoudt G.W., Bangerter F.W., Johnson W.J., Phillips M.C., Rothblat G.H. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 1995, 270:17250-17256.
56. Kimura S., Imai T., Ueno M., Otagiri M. Pharmaceutical evaluation of ibuprofen fast-absorbed syrup containing low-molecular-weight gelatin. J. Pharm. Sci. 1992, 81:141-144.
57. Kobayashi Y., Ohshiro N., Sakai R., Ohbayashi M., Kohyama N., Yamamoto T. Transport mechanism and substrate specify of human organic anion transporter 2 (hOat) [SLC22A7]. J. Pharmacol. 2005, 57:573-578.
58. Kong W., Engel K., Wang J. Mammalian nucleoside transporters. Curr. Drug Metab. 2004, 5:63-84.
59. Krylova O.O., Pohl P. Ionophoric activity of Pluronic block copolymers. Biochemistry 2004, 43:3696-3703.
60. Kunta J.R., Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 2004, 5:109-124.
61. Lavie Y., Fiucci G., Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 1998, 273:32380-32383.
62. Legen I., Kristl A. pH and energy dependent transport of ketoprofen across rat jejunum in vitro. Eur. J. Pharm. Biopharm. 2003, 56:87-94.
63. Legen I., Kristl A. d-Glucose triggers multidrug resitance-associated protein (MRP)-mediated secretion of fluorescein across rat jejunum in vitro. Pharm. Res. 2004, 21:635-640.
64. Legen I., Kracun M., Salobir M., Kerc J. The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. Int. J. Pharm. 2006, 308:84-89.
65. Lo Y.-L. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 2000, 60:1381-1390.
66. London E., Brown D.A. Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim. Biophys. Acta 2000, 1508:182-195.
67. Loth P.T., Lou H.X., Zhao Y., Chin Y.M., Vathsala A. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant. Proc. 2008, 40:1690-1695.
68. Mahato R.I. Pharmaceutical dosage forms and drug delivery. Tablets 2007, CRC Press.
69. Martin G.P., Mariott C., Kellaway I.W. Direct effect of bile salts and phospholipids on the physical properties of mucus. Gut 1978, 19:1103-1107.
70. Meredith D., Boyd C.A.R. Structure and function of eukaryotic peptide transporters. Cell. Mol. Life Sci. 2000, 57:754-778.
71. Miller D.W., Batrakova E.V., Kabanov A.V. Inhibition of multidrug resistance-associated protein (MDR) functional activity with Pluronic block copolymers. Pharm. Res. 1999, 16:396-401.
72. Minato S., Iwanaga K., Kakemi M., Yamashita S., Oku N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J. Control. Rel. 2003, 89:189-197.
73. Mizoguchi H., Wilson A., Jerdack G.R., Hull J.D., Goodale M., Grender J.M., Tyler B.A. Efficacy of a single evening dose syrup containing paracetamol, dextrometorphan hydrobromide, doxylamine succinate and ephedrine sulphate in subjects with multiple common cold symptoms. Int. J. Clin. Pharmacol. Ther. 2007, 45:230-236.
74. Mouly S., Paine M.F. P-glycoprotein increases from proximal to distal regions of human small intestines. Pharm. Res. 2003, 20:1595-1599.
75. Nerurkar M.M., Ho N.F.H., Burton P.S., Vidmar T.J., Borchard R.T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 1997, 86:813-821.
76. Oda M., Saitoh H., Kobayashi M., Aungst B.J. β-Cyclodextrin as suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int. J. Pharm. 2004, 280:95-102.
77. Oku N., Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol. 2005, 391:145-162.
78. Orlowski S., Martin S., Escargueil A. P-glycoprotein and " lipid rafts": some ambiguous mutual relationship (floating on them, building them or meeting them by chance?). Cell. Mol. Life Sci. 2006, 63:1038-1059.
79. Pandit S.A., Vasudevan S., Chiu S.W., Mashl R.J., Jakobsson E., Scott H.L. Sphingomyelin-cholesterol domains in phospholipid membranes: atomistic simulation. Biophys. J. 2004, 87:1092-1100.
80. Park S.C., Kim M., Noh J., Chung H., Woo Y., Lee J., Kemper M.S. Reliable and fast quantitative analysis of active ingredient in pharmaceutical suspension using Raman spectroscopy. Anal. Chim. Acta 2007, 593:46-53.
81. Peng K.C., Cluzeaud F., Bens M., Van Huyen J.P., Wioland M.A., Lacave R., Vandewalle A. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J. Histochem. Cytochem. 1999, 47:757-768.
82. Peppas N.A., Kavimandan N.J. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogel as vehicules delivery. Eur. J. Pharm. Sci. 2006, 29:183-197.
83. Porter C.J.H., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. 2007, 231-248.
84. Rege B.D., Kao J.P.Y., Polli J.E. Effects of non-ionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2002, 16:237-246.
85. Rossi G.A., Tosca M.A., Passalacqua G., Bianchi B., Le Grazie C., Canonica G.W. Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 2005, 60:416-417.
86. Rouge N., Buri P., Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 1996, 136:117-139.
87. Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications 1989, Lea & Febiger, Philadelphia. 2nd ed.
88. Russel T.L., Berardi R.R., Barnett J.L., Dermentzoglou L.C., Jarvenpaa K.M., Schmaltz S.P., Dressman J.B. Upper gastrointestinal pH in seventy-nine healthy elderly North American man and women. Pharm. Res. 2003, 10:187-196.
89. Sakhaee K., Alpern R., Poindexter J., Pak C.Y. Citraturic response to oral citric acid load. J. Urol. 1992, 147:975-976.
90. Scheffer G.L., Maliepart M., Pijnenborg A.C., van Gastelen M.A., de Jong M.C., Schroeijers A.B., van der Kolk D.M., Allen J.D., Ross D.D., van der Valk P., Dalton W.S., Schellens J.H., Scheper R.J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 2000, 60:2589-2593.
91. Semple S.C., Leng E.C., Yuan Z.-N., Eisenhardt M.L., Leone R., Sweet H.L., Dhaliwal P., Namdari R., Flowers C.C., Klimuk S.K. 605 Encapsulation of vinorelbine in sphingomyelin/cholesterol liposomes enhances the tumor exposure and antitumor activity of vinorelbine in human mammary and non-small cell lung cancer solid tumor models. Eur. J. Cancer Suppl. 2004, 2:183.
92. Senior A.E., al-Shawi M.K., Urbatsch I.L. The catalytic cycle of P-glycroprotein. FEBS Lett. 1995, 377:285-289.
93. Seth U.K., Gupta K., Paul T., Pispati P.K. Measurement of antipyretic activity of ibuprofen and paracetamol in children. J. Clin. Pharmacol. 1980, 20:672-675.
94. Shen Q., Lin Y., Handa T., Doi M., Sugie M., Wakayama K., Okada N., Fujita T., Yamamoto A. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 2006, 313:49-56.
95. Shun Y., Liu H. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in vinblastine-resistant human lymphoblastic leukaemia cell line. Biochem. Cell Biol. 2007, 85:638-646.
96. Socaciu C., Jessel R., Diehl H.A. Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy. Chem. Phys. Lipids 2000, 106:79-88.
97. Steffansen B., Nielsen C.U., Brodin B., Eriksson A.H., Andersen R., Frokjaer S. Intestinal solute carriers, an overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci. 2004, 21:3-16.
98. Takahashi K., Kimura Y., Nagata K., Yamamoto A., Matsuo M., Ueda K. ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 2005, 38:2-12.
99. Tayrouz Y., Ding R., Burhenne J., Riedel K.-D., Weiss J., Hoppe-Tichy T., Haefeli W.E., Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and cremophor RH40. Clin. Pharmacol. Ther. 2003, 73:397-405.
100. Tilloy S., Monnaert V., Fenart L., Bricout H., Cecchelli R., Monflier E. Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg. Med. Chem. Lett. 2006, 16:2154-2157.
101. Tomita M., Hyashi M., Horie T., Ishizawa T., Awazu S. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm. Res. 1988, 5:786-789.
102. Tong W.-Q. Biopharmaceutics applications in drug development. Molecular and Physicochemical Properties Impacting Oral Absorption of Drugs 2008, 26-45. Springer, USA. Krishna-Yu (Ed.).
103. Troost J., Lindenmaier H., Haefeli W.E., Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol. Pharmacol. 2004, 66:1332-1339.
104. Uekama K., Hirayama F., Irie T. Cyclodextrine drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
105. Vaughan A.M., Oram J.F. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J. Lipid Res. 2006, 47:2433-2443.
106. Wandel C., Kim R.B., Stein C.M. " Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharmacol. Ther. 2003, 73:394-396.
107. Wang Q., Bhardwaj R.K., Herrera-Ruiz D., Hanna N.N., Gudmundsson O.S., Buranachokpaisan T., Hidalgo I.J., Knipp G.T. Expression of multiple drug resistance conferring proteins in normal Chinese and Caucasian small and large intestinal tissue samples. Mol. Pharm. 2004, 1:447-454.
108. Wang S.-W., Monagle J., McNulty C., Putnam D., Chen H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J. Pharm. Sci. 2004, 93:2755-2767.
109. Weerachayaphorn J., Pajor A.M. Identification of transport pathways for citric acid cycle intermediates in the human colon carcinoma cell line, Caco-2. Biochem. Biophys. Acta 2008, 1778:1051-1059.
110. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., Sugiyama Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. J. Control. Release 2007, 124:1-5.
111. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab. Dispos. 2007, 35:1142-1148.
112. Yamamoto M., Patel N.A., Taggart J., Sridhar R., Cooper D.R. A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells with overproduce PKC-βII. Int. J. Cancer 1999, 83:98-106.
113. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 1997, 14:763-766.
114. You G. The role of organic ion transporters in drug disposition: an update. Curr. Drug Metab. 2004, 5:55-62.
115. Yunomae K., Arima H., Hirayama F., Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 2003, 536:225-231.
116. Zhao H.Z., Tan E.C., Yung L.Y. Potential use of cholescalciferol polyethylene glycol succinate as a novel pharmaceutical additive. J. Biomed. Mater. Res. Part A 2008, 84:954-964.
117. Zimmermann C., Gutmann H., Hruz P., Gutzwiller J.P., Beglinger C., Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 2005, 33:219-224.